Gene Therapy Investment At All Time High, Commercialization Challenges Noted

07 Mar 2019

Investor appetite for cell and gene therapy companies has skyrocketed during the past year. However, storm clouds may gather as manufacturing and reimbursement challenges remain.

2018 saw a huge uptick in investment in gene therapy companies, but the path to efficient manufacture and commercial success for these products is still far from clear, new research from the Alliance for Regenerative Medicine suggests.

2019 has so far continued the trend, kicking off with some big investments in gene therapy companies. Biogen Inc.’s...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

ASCO: Kite’s Glioblastoma CAR-T Highlights Solid Tumor Progress

06 Jun 2025

• By Alaric DeArment

The company presented Phase I data for CART-EGFR-IL13Rα2, showing patient responses in the notoriously hard-to-treat and deadly brain cancer.

ASCO: Kite’s Dual-Targeting CAR-Ts Could Mitigate Toxicity, Resistance

05 Jun 2025

• By Alaric DeArment

Gilead’s Kite division presented Phase I data for its next-generation CAR-T therapy KITE-363 in patients with B-cell lymphomas.

Senti’s Computer-Logic Inspired Cell Therapy Shows Early Promise

29 May 2025

• By Andrew McConaghie

The biotech believes its logic-gated cell therapies can get round the need for ‘clean targets’ which limit CAR-Ts and ADCs.

Strong Data For CARsgen’s CAR-T In Late-Line Gastric Cancer

26 May 2025

• By Dexter Jie Yan

In first confirmatory randomized controlled trial of any CAR-T therapy in solid tumors, CARsgen’s Claudin 18.2-targeting satri-cel reduced risk of death or disease progression by 63% in Chinese patients with gastric/gastroesophageal junction cancer.